Synthetic biology companies surpassed 400 in 2016

13 March 2017

The number of companies in the synthetic biology industry globally has almost doubled over a five-year period, a report shows.

There were 220 companies in this space in 2011, while last year this total was 411, according to the annual Industry Investment Update released on Monday by SynBioBeta, the community of entrepreneurs, investors, policy-makers and enthusiasts devoted to the growth of this field.

In fact the growth in companies slowed for the second-year running in 2016, rising by 24 compared to 41 in 2015 and 53 the previous year. Substantially more than $1 billion was invested into the sector for the first time in 2016, with most of the funding coming from Silicon Valley tech investors, the report notes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK